Sage Therapeutics Inc (NASDAQ:SAGE)
Stock Price:
$50.23
+1.08
(2.2%)
Updated
May 26, 2023 08:00 PM GMT+0000
| Market Cap | 3B |
|---|---|
| Revenue | 9.40M |
| Gross Profit | 8.64M |
| Shares Out | 59.76M |
| EPS (ttm) | -9.38 |
| PE Ratio | -5.3839 |
| Forward PE | -6.0720 |
| Dividend Rate (ttm) | 0.0000 |
| Dividend Yield | 0.0000 |
| Trading Day | May 26 |
|---|---|
| Last Price | $50.23 |
| Previous Close | $49.15 |
| Change ($) | 1.08 |
| Change (%) | 2.2% |
| Day's Open | 49.36 |
| Day's Range | 48.89 - 50.45 |
| Day's Volume | 338.48K |
| 52 Week Range | 30.67 - 54.86 |
About Sage Therapeutics Inc
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. The Company is pursuing new pathways with the goal of improving brain health, and its depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated.
Its mission is to make medicines that matter so people can get better, sooner.
News
Quick info
Country
United States
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Employees
471
CEO
Jeffrey Jonas
Address
215 1st St
Cambridge
Massachusetts
02142-1213
Cambridge
Massachusetts
02142-1213
Phone
16172998380
Website
www.sagerx.com
Ticker Symbol
SAGE
Exchange
NASDAQ Stock Exchange
Reporting Currency
USD
Sage Therapeutics Inc income statements (2022) (USD)
| August 2022 | August 2022 | May 2022 | February 2022 | |
|---|---|---|---|---|
| Total Revenue | 1.50M | 1.50M | 1.58M | 1.64M |
| Cost of Revenue | 200K | 200K | 286K | 87K |
| Gross Profit | 1.30M | 1.30M | 1.30M | 1.56M |
| Research & Development | 77.30M | 77.30M | 78.02M | 75.44M |
| Selling General & Admin | 52.41M | 52.41M | 46.48M | -36.37M |
| Operating Expense | 129.91M | 129.91M | 124.78M | 138.41M |
| Operating Income | -128.41M | -128.41M | -123.2M | -136.77M |
| Other Income Expense Net | 0 | 0 | 0 | 0 |
| EBIT | -128.41M | -128.41M | -123.2M | -136.77M |
| Interest Income | -2.1M | -2.1M | -1.17M | -751K |
| Pretax Income | -126.26M | -126.26M | -122.06M | -124.71M |
| Income Tax | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -126.26M | -126.26M | -122.06M | -124.71M |
| Net Income Basic | -126.26M | -126.26M | -122.06M | -124.71M |
Sage Therapeutics Inc income statements (2021) (USD)
| November 2021 | August 2021 | May 2021 | February 2021 | |
|---|---|---|---|---|
| Total Revenue | 1.44M | 1.64M | 1.58M | 1.11B |
| Cost of Revenue | 131K | 148K | 187K | 136K |
| Gross Profit | 1.31M | 1.50M | 1.40M | 1.11B |
| Research & Development | 83.50M | 66.17M | 58.06M | 81.71M |
| Selling General & Admin | 48.71M | 43.35M | 39.85M | 53.50M |
| Operating Expense | 132.33M | 109.66M | 98.09M | 135.34M |
| Operating Income | -130.89M | -108.02M | -96.51M | 0.97B |
| Other Income Expense Net | 0 | 0 | 0 | 0 |
| EBIT | -130.89M | -108.02M | -96.51M | 0.97B |
| Interest Income | -692K | -732K | -708K | -835K |
| Pretax Income | -130.17M | -107.25M | -95.76M | 0.97B |
| Income Tax | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -130.17M | -107.25M | -95.76M | 0.97B |
| Net Income Basic | -130.17M | -107.25M | -95.76M | 0.97B |
Sage Therapeutics Inc income statements (2020) (USD)
| August 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|
| Total Revenue | 1.09M | 1.09M | 2.29M | 2.29M |
| Cost of Revenue | 110K | 810K | 839K | 839K |
| Gross Profit | 0.98M | 279K | 1.45M | 1.45M |
| Research & Development | 73.32M | 73.32M | 63.61M | 63.61M |
| Selling General & Admin | 38.22M | 37.52M | 69.46M | 69.46M |
| Operating Expense | 111.65M | 111.65M | 133.91M | 133.91M |
| Operating Income | -110.57M | -110.57M | -131.62M | -131.62M |
| Other Income Expense Net | 0 | -25.78M | 4.88M | 4.88M |
| EBIT | -110.57M | -110.57M | -131.62M | -131.62M |
| Interest Income | -2.69M | N.A | N.A | N.A |
| Pretax Income | -136.35M | -136.35M | -126.74M | -126.74M |
| Income Tax | 0 | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -136.35M | -136.35M | -126.74M | -126.74M |
| Net Income Basic | -136.35M | -136.35M | -126.74M | -126.74M |
Sage Therapeutics Inc income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | 1.96M | 3.57M | 873K | 465K |
| Cost of Revenue | 884K | 835K | 549K | 415K |
| Gross Profit | 1.08M | 2.74M | 324K | 50K |
| Research & Development | 91.25M | 102.11M | 89.06M | 86.40M |
| Selling General & Admin | 84.46M | 87.80M | 87.72M | 83.50M |
| Operating Expense | 176.60M | 190.75M | 177.33M | 170.32M |
| Operating Income | -174.64M | -187.18M | -176.46M | -169.85M |
| Other Income Expense Net | 5.99M | 7.22M | 8.24M | 6.45M |
| EBIT | -174.64M | -187.18M | -176.46M | -169.85M |
| Interest Income | N.A | N.A | N.A | N.A |
| Pretax Income | -168.65M | -179.96M | -168.22M | -163.41M |
| Income Tax | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -168.65M | -179.96M | -168.22M | -163.41M |
| Net Income Basic | -168.65M | -179.96M | -168.22M | -163.41M |
Sage Therapeutics Inc income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | N.A | N.A | 90M | N.A |
| Cost of Revenue | N.A | 300K | 200K | 200K |
| Gross Profit | N.A | -300K | 89.80M | -200K |
| Research & Development | 88.81M | 75.05M | 68.98M | 49.27M |
| Selling General & Admin | 74.60M | 53.39M | 42.97M | 28.65M |
| Operating Expense | N.A | 128.75M | 112.15M | 78.12M |
| Operating Income | -164.23M | -128.75M | -22.15M | -78.12M |
| Other Income Expense Net | 5.84M | 5.83M | 5.17M | 3.52M |
| EBIT | -164.23M | -128.75M | -22.15M | -78.12M |
| Interest Income | N.A | N.A | N.A | N.A |
| Pretax Income | -158.39M | -122.92M | -16.98M | -74.6M |
| Income Tax | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -158.39M | -122.92M | -16.98M | -74.6M |
| Net Income Basic | -158.39M | -122.92M | -16.98M | -74.6M |
Sage Therapeutics Inc income statements (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Total Revenue | N.A | N.A | N.A |
| Cost of Revenue | N.A | 136K | 130K |
| Gross Profit | N.A | -136K | -130K |
| Research & Development | 50.89M | 58.29M | 55.90M |
| Selling General & Admin | 19.56M | 15.95M | 14.82M |
| Operating Expense | 70.45M | 74.37M | 70.85M |
| Operating Income | -70.45M | -74.37M | -70.85M |
| Other Income Expense Net | 1.03M | 654K | 652K |
| EBIT | -70.45M | -74.37M | -70.85M |
| Interest Income | N.A | N.A | N.A |
| Pretax Income | -69.42M | -73.72M | -70.2M |
| Income Tax | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 |
| Net Income | -69.42M | -73.72M | -70.2M |
| Net Income Basic | -69.42M | -73.72M | -70.2M |
Sage Therapeutics Inc balance sheet (2023) (USD)
| February 2023 | |
|---|---|
| Current Cash | 1.27B |
| Receivables | 13.66M |
| Inventory | 0 |
| Current Assets | 1.34B |
| Other Current Assets | 50.83M |
| Short Term Investments | 50.83M |
| Long Term Investments | 19.47M |
| Property/Plant Equipment | 2.90M |
| Good Will | N.A |
| Intangible Assets | 0 |
| Tangible Assets (Net) | 1.25B |
| Other Assets | 4.77M |
| Total Assets | 1.36B |
| Accounts Payable | 18.95M |
| Other Current Liabilities | 80.31M |
| Total Current Liabilities | 99.26M |
| Total Liabilities | 103.85M |
| Long Term Debt | 0 |
| Current Long Term Debt | 0 |
| Minority Interest | 0 |
| Common Stock | 59.50M |
| Treasury Stock | -400K |
| Retained Earnings | -2.03B |
| Capital Surplus | N.A |
| Shareholder Equity | 1.25B |
| Other Liabilities | N.A |
Sage Therapeutics Inc balance sheet (2022) (USD)
| August 2022 | August 2022 | May 2022 | February 2022 | |
|---|---|---|---|---|
| Current Cash | 1.51B | 1.51B | 1.63B | 1.74B |
| Receivables | 23.72M | 23.72M | 19.80M | 18.51M |
| Inventory | 0 | 0 | 0 | 0 |
| Current Assets | 1.58B | 1.58B | 1.68B | 1.80B |
| Other Current Assets | 41.46M | 41.46M | 37.21M | 39.84M |
| Short Term Investments | 41.46M | 41.46M | 37.21M | 39.84M |
| Long Term Investments | 22.49M | 22.49M | 23.46M | 24.65M |
| Property/Plant Equipment | 2.94M | 2.94M | 2.84M | 3.02M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Tangible Assets (Net) | 1.50B | 1.50B | 1.62B | 1.73B |
| Other Assets | 4.91M | 4.91M | 4.59M | 4.25M |
| Total Assets | 1.60B | 1.60B | 1.71B | 1.83B |
| Accounts Payable | 5.41M | 5.41M | 7.13M | 10.45M |
| Other Current Liabilities | 83.83M | 83.83M | 70.57M | 74.74M |
| Total Current Liabilities | 89.24M | 89.24M | 77.70M | 85.19M |
| Total Liabilities | 97.14M | 97.14M | 87.20M | 96.26M |
| Long Term Debt | 0 | 0 | 0 | 0 |
| Current Long Term Debt | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 59.27M | 59.27M | 59.03M | 58.67M |
| Treasury Stock | -400K | -400K | -400K | -400K |
| Retained Earnings | -1.74B | -1.74B | -1.62B | -1.5B |
| Capital Surplus | N.A | N.A | N.A | N.A |
| Shareholder Equity | 1.50B | 1.50B | 1.62B | 1.73B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Sage Therapeutics Inc balance sheet (2021) (USD)
| November 2021 | August 2021 | May 2021 | February 2021 | |
|---|---|---|---|---|
| Current Cash | 1.84B | 1.91B | 2B | 2.10B |
| Receivables | 24.19M | 48.44M | 24.77M | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Current Assets | 1.90B | 1.99B | 2.05B | 2.12B |
| Other Current Assets | 34.34M | 28.85M | 23.08M | 22.82M |
| Short Term Investments | 34.34M | 28.85M | 23.08M | 22.82M |
| Long Term Investments | 25.48M | 26.88M | 28.83M | 36.88M |
| Property/Plant Equipment | 2.91M | 3.28M | 4.17M | 6.76M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Tangible Assets (Net) | 1.84B | 1.93B | 2B | 2.07B |
| Other Assets | 3.88M | 3.60M | 3.39M | 3.34M |
| Total Assets | 1.93B | 2.02B | 2.08B | 2.16B |
| Accounts Payable | 4.73M | 2.92M | 3.29M | 3.69M |
| Other Current Liabilities | 74.21M | 68.98M | 58.73M | 63.51M |
| Total Current Liabilities | 78.94M | 71.90M | 62.01M | 67.20M |
| Total Liabilities | 91.53M | 85.96M | 77.42M | 86.91M |
| Long Term Debt | 0 | 0 | 0 | 0 |
| Current Long Term Debt | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 58.82M | 58.58M | 58.37M | 51.98M |
| Treasury Stock | -400K | -400K | -400K | -400K |
| Retained Earnings | -1.37B | -1.24B | -1.13B | -1.04B |
| Capital Surplus | N.A | N.A | N.A | N.A |
| Shareholder Equity | 1.84B | 1.93B | 2B | 2.07B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Sage Therapeutics Inc balance sheet (2020) (USD)
| August 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|
| Current Cash | 756.52M | 258.23M | 199.44M | 199.44M |
| Receivables | 0 | N.A | N.A | N.A |
| Inventory | 0 | N.A | N.A | N.A |
| Current Assets | 785.38M | 785.38M | 898.24M | 898.24M |
| Other Current Assets | 28.86M | 28.86M | 25.48M | 25.48M |
| Short Term Investments | 28.86M | 498.29M | 673.31M | 673.31M |
| Long Term Investments | 41.86M | 2.37M | 2.37M | 2.37M |
| Property/Plant Equipment | 8.08M | 36.08M | 40.68M | 40.68M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 0 | N.A | N.A | N.A |
| Tangible Assets (Net) | 739.92M | 739.92M | 849.21M | 849.21M |
| Other Assets | 3.42M | 3.42M | 3.69M | 3.69M |
| Total Assets | 827.24M | 827.24M | 0.94B | 0.94B |
| Accounts Payable | 2.39M | 2.39M | 7.91M | 7.91M |
| Other Current Liabilities | 61.91M | 53.33M | 52.18M | 52.18M |
| Total Current Liabilities | 64.29M | 64.29M | 70.36M | 70.36M |
| Total Liabilities | 87.33M | 87.33M | 95.77M | 95.77M |
| Long Term Debt | 0 | 22.66M | 24.95M | 24.95M |
| Current Long Term Debt | 0 | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 2.65B | 51.93M | 51.92M | 51.92M |
| Treasury Stock | -400K | 400K | 400K | 400K |
| Retained Earnings | -1.91B | -1.91B | -1.77B | -1.77B |
| Capital Surplus | N.A | 2.65B | 2.62B | 2.62B |
| Shareholder Equity | 739.92M | 739.92M | 849.21M | 849.21M |
| Other Liabilities | N.A | N.A | N.A | N.A |
Sage Therapeutics Inc balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 126.71M | 259.18M | 166.19M | 342.30M |
| Receivables | N.A | N.A | N.A | N.A |
| Inventory | N.A | N.A | N.A | N.A |
| Current Assets | 1.04B | 1.15B | 1.26B | 1.37B |
| Other Current Assets | 26.70M | 30.41M | 27.02M | 20.28M |
| Short Term Investments | 881.69M | 863.07M | 1.07B | 1.01B |
| Long Term Investments | 2.37M | 2.37M | 2.37M | 2.37M |
| Property/Plant Equipment | 42.90M | 44.88M | 45.59M | 44.64M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A | N.A |
| Tangible Assets (Net) | 0.94B | 1.08B | 1.20B | 1.32B |
| Other Assets | 3.79M | 3.82M | 4.02M | 4.38M |
| Total Assets | 1.08B | 1.20B | 1.32B | 1.42B |
| Accounts Payable | 15.27M | 5.04M | 12.43M | 13.56M |
| Other Current Liabilities | 86.62M | 78.36M | 59.13M | 47.67M |
| Total Current Liabilities | 112.13M | 90.96M | 78.95M | 68.38M |
| Total Liabilities | 139.50M | 122.66M | 112.67M | 103.38M |
| Long Term Debt | 26.85M | 31.36M | 33.31M | 34.53M |
| Current Long Term Debt | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 51.88M | 51.82M | 51.47M | 51.03M |
| Treasury Stock | 400K | 400K | 400K | 400K |
| Retained Earnings | -1.64B | -1.47B | -1.29B | -1.13B |
| Capital Surplus | 2.59B | 2.55B | 2.50B | 2.45B |
| Shareholder Equity | 0.94B | 1.08B | 1.20B | 1.32B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Sage Therapeutics Inc balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 190.94M | 253.12M | 325.83M | 557.56M |
| Receivables | N.A | N.A | N.A | N.A |
| Inventory | N.A | N.A | N.A | N.A |
| Current Assets | 0.94B | 1.04B | 1.12B | 1.10B |
| Other Current Assets | 21.92M | 18.51M | 12.96M | 11.58M |
| Short Term Investments | 731.83M | 768.28M | 766.60M | 525.96M |
| Long Term Investments | 2.37M | 1.92M | 1.27M | 1.27M |
| Property/Plant Equipment | 5.64M | 5.17M | 4.45M | 4.30M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A | N.A |
| Tangible Assets (Net) | 862.97M | 0.99B | 1.08B | 1.06B |
| Other Assets | N.A | N.A | N.A | N.A |
| Total Assets | 0.95B | 1.05B | 1.13B | 1.10B |
| Accounts Payable | 34.04M | 5.88M | 8.34M | 8.35M |
| Other Current Liabilities | 51.99M | 48.65M | 39.58M | 29.52M |
| Total Current Liabilities | 86.03M | 54.53M | 47.92M | 37.87M |
| Total Liabilities | 89.73M | 58.49M | 51.72M | 41.38M |
| Long Term Debt | N.A | N.A | N.A | N.A |
| Current Long Term Debt | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 46.89M | 46.83M | 46.60M | 46.46M |
| Treasury Stock | 211K | 211K | 211K | 211K |
| Retained Earnings | -0.96B | -804.94M | -682.02M | -665.05M |
| Capital Surplus | 1.83B | 1.79B | 1.76B | 1.72B |
| Shareholder Equity | 862.97M | 0.99B | 1.08B | 1.06B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Sage Therapeutics Inc balance sheet (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Current Cash | 306.24M | 134.92M | 133.45M |
| Receivables | N.A | N.A | N.A |
| Inventory | N.A | N.A | N.A |
| Current Assets | 525.08M | 248.34M | 291.12M |
| Other Current Assets | 6.23M | 4.89M | 5.19M |
| Short Term Investments | 212.61M | 108.54M | 152.48M |
| Long Term Investments | 849K | 849K | 849K |
| Property/Plant Equipment | 4.01M | 1.89M | 1.44M |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A |
| Tangible Assets (Net) | 475.48M | 200.05M | 260.30M |
| Other Assets | N.A | N.A | N.A |
| Total Assets | 529.94M | 251.09M | 293.41M |
| Accounts Payable | 9.35M | 13.03M | 6.04M |
| Other Current Liabilities | 42.60M | 36.81M | 26.24M |
| Total Current Liabilities | 51.95M | 49.84M | 32.28M |
| Total Liabilities | 54.46M | 51.03M | 33.11M |
| Long Term Debt | N.A | N.A | N.A |
| Current Long Term Debt | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 |
| Common Stock | 42M | 37.52M | 37.42M |
| Treasury Stock | 113K | 17K | 17K |
| Retained Earnings | -590.45M | -521.03M | -447.31M |
| Capital Surplus | 1.07B | 721.11M | 707.69M |
| Shareholder Equity | 475.48M | 200.05M | 260.30M |
| Other Liabilities | N.A | N.A | N.A |
Sage Therapeutics Inc cash flow (2023) (USD)
| February 2023 | |
|---|---|
| Net Income | -147.15M |
| Depreciation | 290K |
| Changes in Receivables | 13.66M |
| Changes in Inventories | 0 |
| Cash Change | 1.27B |
| Cash Flow | -126.93M |
| Capital Expenditures | -282K |
| Investments | N.A |
| Investing Activity (other) | N.A |
| Total Investing Cash Flows | 89.78M |
| Dividends Paid | N.A |
| Net Borrowings | -1.32B |
| Other Financing Cash Flows | N.A |
| Cash Flow Financing | 29K |
| Exchange Rate Effect | N.A |
Sage Therapeutics Inc cash flow (2022) (USD)
| November 2022 | August 2022 | |
|---|---|---|
| Net Income | -137.32M | -126.26M |
| Depreciation | 278K | 279K |
| Changes in Receivables | 18.45M | 23.72M |
| Changes in Inventories | 0 | 0 |
| Cash Change | 1.39B | 1.51B |
| Cash Flow | -118.87M | -106.44M |
| Capital Expenditures | -364K | -122K |
| Investments | N.A | N.A |
| Investing Activity (other) | N.A | N.A |
| Total Investing Cash Flows | 110.95M | 134.26M |
| Dividends Paid | N.A | N.A |
| Net Borrowings | -1.45B | -1.56B |
| Other Financing Cash Flows | N.A | N.A |
| Cash Flow Financing | 1.23M | 13K |
| Exchange Rate Effect | N.A | N.A |
Sage Therapeutics Inc cash flow (2021) (USD)
| November 2021 | |
|---|---|
| Net Income | -130.17M |
| Depreciation | 374K |
| Changes in Receivables | 24.19M |
| Changes in Inventories | 0 |
| Cash Change | 1.84B |
| Cash Flow | -68.83M |
| Capital Expenditures | -1.67B |
| Investments | N.A |
| Investing Activity (other) | N.A |
| Total Investing Cash Flows | -1.92B |
| Dividends Paid | N.A |
| Net Borrowings | -1.88B |
| Other Financing Cash Flows | N.A |
| Cash Flow Financing | 1.82M |
| Exchange Rate Effect | N.A |
Sage Therapeutics Inc cash flow (2020) (USD)
| August 2020 | June 2020 | March 2020 | |
|---|---|---|---|
| Net Income | -136.35M | -136.35M | -126.74M |
| Depreciation | 1.33M | 662K | 669K |
| Changes in Receivables | 0 | N.A | N.A |
| Changes in Inventories | 0 | N.A | N.A |
| Cash Change | -116.24M | 58.78M | 72.74M |
| Cash Flow | -255.68M | -117.21M | -134.82M |
| Capital Expenditures | -346K | -70K | -276K |
| Investments | N.A | 177.45M | 206.55M |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | 383.65M | 177.38M | 206.27M |
| Dividends Paid | N.A | N.A | N.A |
| Net Borrowings | -785.38M | -1.78M | -1.87M |
| Other Financing Cash Flows | N.A | N.A | N.A |
| Cash Flow Financing | 3.55M | -1.39M | 1.29M |
| Exchange Rate Effect | N.A | N.A | N.A |
Sage Therapeutics Inc cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | -168.65M | -179.96M | -168.22M | -163.41M |
| Depreciation | 665K | 698K | 505K | 415K |
| Changes in Receivables | N.A | N.A | N.A | N.A |
| Changes in Inventories | N.A | N.A | N.A | N.A |
| Cash Change | -132.48M | 88.65M | -171.76M | 151.35M |
| Cash Flow | -125.66M | -126.92M | -129M | -149.93M |
| Capital Expenditures | -373K | -1.94M | -2.18M | -1.26M |
| Investments | -17.54M | 209.72M | -55.93M | -273.65M |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -17.92M | 207.78M | -58.11M | -274.91M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | 8.94M | -6.13M | N.A | N.A |
| Other Financing Cash Flows | N.A | -1.48M | N.A | -692K |
| Cash Flow Financing | 11.10M | 7.79M | 15.34M | 576.20M |
| Exchange Rate Effect | N.A | N.A | N.A | N.A |
Sage Therapeutics Inc cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | -158.39M | -122.92M | -16.98M | -74.6M |
| Depreciation | 363K | 287K | 246K | 247K |
| Changes in Receivables | N.A | N.A | N.A | N.A |
| Changes in Inventories | N.A | N.A | N.A | N.A |
| Cash Change | -61.73M | -72.06M | -231.73M | 251.74M |
| Cash Flow | -101.78M | -80.19M | -135K | -78.57M |
| Capital Expenditures | -808K | -1M | -402K | -652K |
| Investments | 39.23M | 1.05M | -237.73M | -312.15M |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | 38.42M | 52K | -238.13M | -312.8M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A | N.A | -0.9M |
| Cash Flow Financing | 1.63M | 8.08M | 6.54M | 643.11M |
| Exchange Rate Effect | N.A | N.A | N.A | N.A |
Sage Therapeutics Inc cash flow (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Net Income | -69.42M | -73.72M | -70.2M |
| Depreciation | 135K | 136K | 130K |
| Changes in Receivables | N.A | N.A | N.A |
| Changes in Inventories | N.A | N.A | N.A |
| Cash Change | 171.32M | 1.47M | -12.01M |
| Cash Flow | -58.9M | -46.09M | -59.08M |
| Capital Expenditures | -804K | -235K | -76K |
| Investments | -103.8M | 44.11M | 44.38M |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | -104.6M | 43.87M | 44.31M |
| Dividends Paid | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A | N.A |
| Cash Flow Financing | 334.82M | 3.69M | 2.76M |
| Exchange Rate Effect | N.A | N.A | N.A |
Sage Therapeutics Inc dividends (USD)
Total Valuation
Sage Therapeutics Inc has a market cap or net worth of $3 billion. The enterprise value is $1.87 billion.
Market Cap
3B
Enterprise Value
1.87B
Important Dates
Earnings Date
Aug 1, 2023
Ex-Dividend Date
n.a
Share Statistics
Sage Therapeutics Inc has 59.76 million shares outstanding.
Shares Outstanding
59.76M
Float
n.a
Valuation Ratios
The trailing PE ratio is -5.3839 and the forward PE ratio is -6.0720. Sage Therapeutics Inc's PEG ratio is 0.3866.
PE Ratio
-5.3839
Forward PE
-6.0720
PS Ratio
319.4100
PB Ratio
2.6500
PEG Ratio
0.3866
Stock Price Statistics
The stock price has increased by 0.3170%. The beta is 1.0816, so Sage Therapeutics Inc's price volatility has been higher than the market average.
Beta (1Y)
1.0816
52-Week Price Change
+0.3170%
50-Day Moving Average
48.74
200-Day Moving Average
43.32
Average Volume (30 Days)
534.86K
Income Statement
In the last 12 months, Sage Therapeutics Inc had revenue of $9.40 million and earned $8.64 million in profits. Earnings per share was $-9.38.
Revenue
9.40M
Gross Profit
8.64M
EBITDA
-580.32M
Earnings per Share
-9.38
About
Ticker Symbol
SAGE
Reporting Currency
USD
Key Executives
Greene Barry E
President and CEO
Kanes Stephen
Chief Medical Officer
JONAS JEFFREY M
Chief Executive Officer
IGUCHI KIMI
Chief Financial Officer, Secretary and Treasurer